6/28/23, 11:16 PM METEORIC-HF Pathway Feedback Search Clinical Topics Home Studies METEORIC HF METEORIC HF Disease Heart failure Trial question What is the effect of omecamtiv mecarbil, a novel cardiac myosin activator, in patients with chronic HFrEF? Study design Multi-center Double blinded RCT Population Characteristics of study participants 15.0% female N = 276 85.0% male 276 patients (42 female, 234 male) Inclusion criteria: patients with chronic HFrEF Key exclusion criteria: major medical event or procedure within the previous 3 months; conditions limiting exercise capacity during exercise testing; inability to achieve a respiratory exchange ratio 1.05 on baseline cardiopulmonary exercise testing Interventions N=185 omecamtiv mecarbil (a dose of 25 mg, 37.5 mg, or 50 mg based on target plasma levels for 20 weeks) N=91 placebo (matching placebo) https://web.pathway.md/studies/recGSPAiJY7hXmQRJ 1/2 6/28/23, 11:16 PM METEORIC-HF Pathway Primary outcome No significant difference in improvement in exercise capacity after 20 weeks of therapy (-0.24 mL/kg/min vs. 0.21 mL/kg/min; AD -0.45 mL/kg/min, 95% CI -1.02 to 0.13) Secondary outcomes No significant difference in improvement in ventilatory efficiency (0.28 vs. -0.14; AD 0.41, 95% CI -0.8 to 1.6) No significant difference in improvement in total daily activities by actigraphy (-0.2 vs. -0.5; AD 0.3, 95% CI -0.6 to 1.1) Significant decrease in improvement in peak workload achieved (-3.8 W vs. 1.6 W; AD -5.4 W, 95% CI -10.1 to -0.7) Safety outcomes No significant difference in adverse events. Conclusion In patients with chronic HFrEF, omecamtiv mecarbil was not superior to placebo with respect to improvement in exercise capacity after 20 weeks of therapy. Reference Gregory D Lewis, Adriaan A Voors, Alain Cohen-Solal et al. Effect of Omecamtiv Mecarbil on Exercise Capacity in Chronic Heart Failure With Reduced Ejection Fraction: The METEORIC-HF Randomized Clinical Trial. JAMA. 2022 Jul 19;328(3):259-269. Open reference URL https://web.pathway.md/studies/recGSPAiJY7hXmQRJ 2/2